Indolent Lymphoma
Links shared publicly online about this topic
Watchful Waiting and Monitoring Indolent Lymphomas
lymphomation.org — “Watchful Waiting and Monitoring Indolent Lymphomas” View full resource at lymphomation.org
Most Recently Shared on August 18, 2009 at 4:35 am By:
Lymphomation's Karl Schwartz on Watchful Waiting in indolent #lymphoma. http://bit.ly/DzGMb
MD Consult: News: Bendamustine outshines CHOP in indolent lymphoma
mdconsult.com — “MD Consult: News: Bendamustine outshines CHOP in indolent lymphoma” View full resource at mdconsult.com
Most Recently Shared on December 8, 2009 at 5:30 pm By:
MD Consult Health Site and Medical Publisher
Bendamustine outshines CHOP in indolent lymphoma http://bit.ly/7E0unu
Lenalidomide Therapy In Previously Untreated, Advanced Stage Indolent Lymphoma - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Lenalidomide Therapy In Previously Untreated, Advanced Stage Indolent Lymphoma - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on August 16, 2010 at 5:30 pm By:
study of interest: Lenalidomide In Previously Untreated, Advanced Stage Indolent #Lymphoma http://bit.ly/b3xIvp
Indolent Lymphoma: Can Rituximab Resolve the Watch-and-Wait Debate? -- Ross 102 (4): 220 -- JNCI Journal of the National Cancer Institute
jnci.oxfordjournals.org — “Indolent Lymphoma: Can Rituximab Resolve the Watch-and-Wait Debate? -- Ross 102 (4): 220 -- JNCI Journal of the National Cancer Institute” View full resource at jnci.oxfordjournals.org
Most Recently Shared on February 12, 2010 at 9:18 pm By:
J Nat'l Cancer Inst Oncology and Medical Journal
JNCI news story: Indolent lymphoma: to treat or to watch and wait? Will rituximab resolve that debate? http://bit.ly/9UgIge
Medical News: ASH: New Combo Challenges Standard Treatment for Indolent Lymphomas - in Meeting Coverage, ASH: Hematology from MedPage Today
medpagetoday.com — “NEW ORLEANS -- Bendamustine (Treanda) could replace the so-called CHOP regimen as the optimal partner with rituximab as the standard first-line treatment for indolent and mantle cell lymphomas, resear” View full resource at medpagetoday.com
Most Recently Shared on December 6, 2009 at 5:29 am By:
ASH: New Combo Challenges Standard Treatment for Indolent Lymphomas (CME/CE) http://ow.ly/1671Wn
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma | Reuters
reuters.com — “Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma Overview of Phase II-III Clinical Trials will be Presented at International Lymphoma” View full resource at reuters.com
Most Recently Shared on October 22, 2009 at 2:06 pm By:
Drug Pixantrone produces high rates of complete remission in Multiple relapse of NHLs & Hodgkins. http://bit.ly/4BuLSU
Lymphoma on #MDlinx
mdlinx.com — “Lymphoma on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on October 8, 2010 at 12:56 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extran... http://bit.ly/c112CJ #oncology
Lymphoma in the News: Lenalidomide Plus Rituximab Shows Promise as First-Line Therapy in Patients with Indolent Non-Hodgkin Lymphoma « New Developments in Lymphoma
cornell-lymphoma.com — “Lymphoma in the News: Lenalidomide Plus Rituximab Shows Promise as First-Line Therapy in Patients with Indolent Non-Hodgkin Lymphoma « New Developments in Lymphoma” View full resource at cornell-lymphoma.com
Most Recently Shared on July 22, 2011 at 1:36 pm By:
Lenalidomide Plus Rituximab Shows Promise as First-Line Therapy in Patients with Indolent #Lymphoma http://t.co/NK7NvgG
Lymphoma on #MDlinx
mdlinx.com — “Lymphoma on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on October 7, 2010 at 3:34 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Radio-immunotherapy of indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10... http://bit.ly/djdVOF #oncology
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study - Full Text Vi
clinicaltrials.gov — “Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on February 13, 2010 at 2:36 am By:
Multi-center US Clinical Trial (recruiting & soon to be recruiting): Bendamustine + R vs. CHOP+R for indolent lymphoma. http://bit.ly/bMVHXW
Oncology Article | Lymphoma
mdlinx.com — “Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points” View full resource at mdlinx.com
Most Recently Shared on February 9, 2011 at 4:13 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Identification of potential surrogate end points in randomized clinical trials of aggressive and indol... http://bit.ly/eEkIGp #oncology
Patients- Against-Lymphoma | Facebook
facebook.com — “Patients- Against-Lymphoma is on Facebook. Join Facebook to connect with Patients- Against-Lymphoma and others you may know. Facebook gives people the power to share and makes the world more open and connected. Patients- Against-Lymphoma is a fan of 194 Pages on Facebook.” View full resource at facebook.com
Most Recently Shared on April 16, 2010 at 1:12 pm By:
RIT for indolent lymphomas is safe for repeat use. http://bit.ly/bvU4Xi
Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab Produces High Rates of Complete Remissions in Patients with Relapsed or Refractory Indolent Non-Hodgkins Lymphoma - Drugs.com MedNews
drugs.com — “- Results published in Cancer Cell Therapeutics, Inc. ( CTI ) (NASDAQ and MTA CTIC) announced the publication of results posted in the online journal of Cancer” View full resource at drugs.com
Most Recently Shared on June 17, 2011 at 1:04 pm By:
Drugs and Devices OW OW Health
Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab Produces High Rates of Complete Re... http://bit.ly/l7cg8P #drug
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study -- Friedberg et al. 26 (2): 204 -- Journal of Clinical Oncology
jco.ascopubs.org — “Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study -- Friedberg et al. 26 (2): 204 -- Journal of Clinical Oncology” View full resource at jco.ascopubs.org
Most Recently Shared on September 29, 2009 at 4:10 pm By:
Emerging treatments for indolent lymphoma http://bit.ly/17omZT Bendamustine, investigational drug: http://bit.ly/N8BqO
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma - Nagai - European Journal of Haematology - Wiley Online Library
onlinelibrary.wiley.com — “Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma - Nagai - European Journal of Haematology - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on November 12, 2010 at 8:03 pm By:
Cladribine combined with rituximab (Râ€*2â€*CdA) therapy is an effective salvage therapy in relapsed or refracto... http://bit.ly/ar8rPO
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Lymphomation.org
Lymphomation.org/Patients Against Lymphoma -- Providing support and timely access to evidence-based information on lymphomas and their treatment.
-
MD Consult
Twitter news features the latest medical news from MD Consult. MD Consult combines the in-depth content of tmedicine's leading books, journals, and review articles with the succinct and evidence-based point-of-care content of First Consult to provide trusted answers in one place. Physicians log over 1.7 million searches each month on MD Consult. MD Consult - Find the answer.
-
Lymphomation.org
Lymphomation.org/Patients Against Lymphoma -- Providing support and timely access to evidence-based information on lymphomas and their treatment.
Advertisement
